Log in to save to my catalogue

Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previou...

Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previou...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04244552v1

Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R
FLT3
-mutated AML patients. Among them, 140 received gilteritinib as single agent (cohort B), including 67 previously treated by intensive chemotherapy and midostaurin (cohort C). The main differences in patient characteristics in th...

Alternative Titles

Full title

Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_04244552v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04244552v1

Other Identifiers

ISSN

0887-6924

E-ISSN

1476-5551

DOI

10.1038/s41375-022-01742-7

How to access this item